Celldex Therapeutics, Inc.
- Nasdaq
- CLDX
- CIK
- 744218
- Based in
- Hampton, New Jersey
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Employer ID (EIN)
- 13-3191702
- Formerly
- Avant Immunotherapeutics Inc, T Cell Sciences Inc
About
AI summary. This paragraph was summarized by AI from the company’s annual report. It may contain mistakes: check it against the source. How it was written
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on mast cell biology and the development of therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune and other diseases. Its drug candidates include monoclonal and bispecific antibodies aimed at mast cell mediated diseases. Its lead candidate, barzolvolimab (CDX-0159), is a humanized monoclonal antibody that binds and inhibits the KIT receptor, and it is in clinical studies for chronic spontaneous urticaria, cold urticaria, symptomatic dermographism, prurigo nodularis and atopic dermatitis. The company also has a bispecific antibody platform, whose first candidate, CDX-622, targets TSLP and SCF and is in Phase 1 studies. Celldex has had no commercial revenues from sales of its drug candidates, and its Phase 3 urticaria trials span sites in multiple countries.
Source: the Business section of the company’s 10-K filed Feb 25, 2026.
Key figures
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | $1.54M | $7.02M | $6.88M | $2.36M | $4.65M |
| Operating income | −$287.4M | −$195.1M | −$154.5M | −$115.2M | −$71.2M |
| Net income | −$258.8M | −$157.9M | −$141.4M | −$112.3M | −$70.5M |
| Diluted EPS | −$3.90 | −$2.45 | −$2.92 | −$2.40 | −$1.64 |
| Cash from operations | −$210.9M | −$157.8M | −$107.3M | −$103.7M | −$60.9M |
| Total assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M |
| Shareholders’ equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M |
From the company’s annual reports to the SEC. Each year links to its report.
Financials 140
- 10-Q Quarterly Report for period ending Sep 30, 2026
- 10-Q Quarterly Report for period ending Jun 30, 2026
- 10-Q Quarterly Report for period ending Mar 31, 2026
- 10-K Annual Report for period ending Dec 31, 2025
- 10-Q Quarterly Report for period ending Sep 30, 2025
- 10-Q Quarterly Report for period ending Jun 30, 2025
- 10-Q Quarterly Report for period ending Mar 31, 2025
- 10-K Annual Report for period ending Dec 31, 2024
- 10-Q Quarterly Report for period ending Sep 30, 2024
- 10-Q Quarterly Report for period ending Jun 30, 2024
News 239
Ownership 698
- SCHEDULE 13G/A Major shareholder report (passive investor)
- SCHEDULE 13G/A Major shareholder report (passive investor)
- SCHEDULE 13G/A Major shareholder report (passive investor)
- SCHEDULE 13G Major shareholder report (passive investor)
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
Prospectus 121
- S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
Proxies 38
- DEF 14A Definitive proxy statements
- DEF 14A Definitive proxy statements
- DEF 14A Definitive proxy statements
- DEF 14A Definitive proxy statements
- DEF 14A Definitive proxy statements
- DEF 14A Definitive proxy statements
- DEF 14A Definitive proxy statements
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- DEF 14A Definitive proxy statements
Other 63
- ARS Annual report to security holders
- ARS Annual report to security holders
- ARS Annual report to security holders
- ARS Annual report to security holders
- EFFECT Notice of Effectiveness
- CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
- UPLOAD Letter (PDF)
- CT ORDER Order Granting Confidential Treatment
- EFFECT Notice of Effectiveness
- EFFECT Notice of Effectiveness